• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    Aethlon Medical, Inc. (AEMD)

    -Other OTC
    0.28 0.00(0.36%) Dec 24, 12:57PM EST
    |Pre-Market : NaN
    Add to Portfolio
    ProfileGet Profile for:
    Aethlon Medical, Inc.
    9635 Granite Ridge Drive
    Suite 100
    San Diego, CA 92123
    United States - Map
    Phone: 858-459-7800
    Fax: 858-272-2738
    Website: http://www.aethlonmedical.com

    Index Membership:N/A
    Industry:Medical Appliances & Equipment
    Full Time Employees:10

    Business Summary 

    Aethlon Medical, Inc. operates as a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was formerly known as Bishop Equities Inc and changed its name to Aethlon Medical, Inc. in March 2000. The company was founded in 1991 and is based in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Aethlon Medical, Inc.

    Key Executives 
    Mr. James A. Joyce Ph.D., 52
    Founder, Chairman, Chief Exec. Officer, Principal Accounting Officer and Sec.
    Mr. Rodney S. Kenley , 64
    Pres and Director
    Mr. James B. Frakes , 57
    Chief Financial Officer and Sr. VP of Fin.
    Dr. Richard H. Tullis Ph.D., 68
    Chief Scientific Officer, VP and Director
    Mr. John P. Salvador ,
    Director of Communications and Investor Relations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders